Nike Kicks Off Multi-Year Innovation Cycle
11.4.2024 21:31:00 EEST | Business Wire | Press release
Today, NIKE, Inc. (NYSE: NKE) extended its position as the undisputed leader of footwear and apparel innovation by debuting a new line-up of products that signaled a multi-year innovation cycle. Brought to life by the full power of digital capabilities and cutting-edge technology, the company is delivering better, faster, more efficient solutions for athletes this summer and opening a world of creative possibilities — including Nike's first sculpted, visible Air Zoom unit in the new Pegasus Premium running shoe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411422311/en/
Harnessing its proprietary Air technology, Nike debuts the Nike Pegasus Premium – taking the cushioning that runners love from the iconic Pegasus franchise and adding Nike’s first sculpted, visible Air Zoom unit. The new, sculpted Air Zoom unit is the brand’s biggest Air innovation since the launch of the Nike Air VaporMax. (Photo: Business Wire)
The proprietary, sculpted Air unit connects the heel and forefoot and uniquely contours to the natural profile of the foot, delivering an entirely new springy, smooth sensation. Combined with ZoomX and ReactX foam, the new cushioning system creates more energy return for everyday runners.
In addition, Air, Nike’s most revolutionary, ubiquitous and versatile cushioning platform, powers the products Nike athletes will wear on the track, court and pitch this summer. Nike has optimized Air by leveraging computational design and incomparable athlete data from the Nike Sport Research Lab to create footwear that helps all athletes break barriers.
“For more than 50 years we’ve listened to and over-delivered for our athletes with the best of Nike innovation. We always push the boundaries of what’s possible and take risks to help create the future of sport together,” said John Hoke, Nike’s Chief Innovation Officer. “This summer, the difference maker is the massive energy return that Nike Air delivers to athletes. Taking what we learned from our super-shoe technology, we’re introducing new Nike Air Zoom shapes and sensations across all sports.”
The best of Nike’s Air innovation for this summer will debut in the Nike Blueprint Pack, spanning footwear for track and road racing, basketball, football, skate, breakdancing and lifestyle. The blue, white and orange colorway is a nod to Nike’s co-founder, Bill Bowerman, and his obsession with enabling the best-possible athlete performance.
Nike’s world-class athletes, including Dina Asher-Smith, Shelly-Ann Fraser-Pryce, Eliud Kipchoge and Sha’Carri Richardson, revealed the brand’s 2024 federation kits, which are the most data-driven and visually unified Nike’s ever produced. Based on 4D motion-capture data, with pixel-level precision and specifically designed for each competition, the kits were inspired by the distinct identities and diverse communities of each country and sport.
Nike also revealed A.I.R. — Athlete Imagined Revolution. In this co-creation project between elite athletes and Nike designers, Nike used innovative design tools to create the future of Air. The radical concepts are a view into the future of athlete co-creation, as well as the unlimited possibilities of Nike Air.
“There are now no limits to what we can create with Nike Air,” said Hoke. “We’re obsessing new technologies like AI engines and rapid prototyping to continue exploring the unlimited possibilities. Now we can create Nike products with unprecedented fidelity, velocity and impact.”
“We’re thrilled to celebrate another summer of sport with our incredible athletes and the product innovations that will help propel them to achieve their dreams,” said Heidi O’Neill, President, Consumer, Product and Brand, NIKE, Inc. “What you’ll see this year on the pitch, court, road or track signals a new, exciting multi-year cycle of innovation for us. And this summer is just a hint of the game-changing innovations coming across our entire portfolio that will take us into new markets and market share opportunities.”
NIKE, Inc., based near Beaverton, Ore., is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE, Inc.’s earnings releases and other financial information are available on the Internet at http://investors.nike.com. Individuals can also visit http://news.nike.com and follow @NIKE.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411422311/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom